Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): January 8, 2013
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Extension of Employment Agreement with Jonathan Lewis, M.D., Ph.D.
On January 8, 2013, ZIOPHARM Oncology, Inc., or the Company, extended the term of its existing employment agreement with Jonathan Lewis, M.D., Ph.D., the Company’s Chief Executive Officer, for an additional one year period expiring January 8, 2014. Dr. Lewis’ employment agreement, as previously extended, was scheduled to expire by its terms on January 8, 2013. A copy of the Extension of Employment Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INDEX OF EXHIBITS